News

FDA Recall: Tylenol Cold Products and Children's Benadryl, Motrin


 

The Food and Drug Administration has announced recalls of three types of over-the-counter medications by McNeil Consumer Healthcare.

Consumers may continue to take previously purchased products, and no action is required by health care providers.

Three Tylenol Cold Multi-Symptom liquid products sold in the United States (Daytime 8-ounce Citrus Burst liquid, Severe 8-ounce Cool Burst Liquid, and Nighttime 8-ounce Cool Burst Liquid) were recalled Nov. 24. No adverse events were reported, but the product labeling needs to be updated to more prominently note the small (less than 1%) presence of alcohol from flavoring agents as an inactive ingredient. This ingredient had been listed on the package but not on the front of the medicine bottle. Tylenol’s maker, McNeil Consumer Healthcare, began the recall after an internal company review identified this issue. The FDA says that health care providers do not need to take any action as a result of the recall, and consumers may continue to use the medicine.

McNeil also issued a voluntary recall of all product lots of Children’s Benadryl Allergy Fastmelt Tablet in cherry and grape flavors that were sold in the United States, Belize, Barbados, Canada, Puerto Rico, St. Martin and St. Thomas, as well as all Junior Strength Motrin Caplets 24 count that were sold in the United States. These recalls, issued Nov. 15, are the result of a review that found insufficiencies in the development of the manufacturing process. Consumers may continue to use these products, and no action is required for health care providers, according to the FDA. There is no reason to believe that the products are unsafe, and no adverse events have been reported.

Questions about the recalls should be directed to the company’s Consumer Care Center at 1-888-222-6036.

Recommended Reading

Commentary: The Child With Food Allergy
MDedge Dermatology
Compliance May Be Biggest Treatment Barrier in Atopy
MDedge Dermatology
Blog: Highlight Evidence When Explaining Atopy to Parents
MDedge Dermatology
EADV: Exploring the Hapten Hypothesis of Atopic Disease
MDedge Dermatology
Sunscreens Don't Always Live Up to Advertising Promises
MDedge Dermatology
Aprepitant Relieves Refractory Chronic Pruritus
MDedge Dermatology
When to Consider Allergic Contact Dermatitis in an Atopic Child
MDedge Dermatology
Contact Irritants Can Incite Atopic Dermatitis in Children
MDedge Dermatology
Improvement in Treatment Adherence With a 3-Day Course of Fluocinonide Cream 0.1% for Atopic Dermatitis
MDedge Dermatology
Pediatric Molluscum Contagiosum: Reflections on the Last Challenging Poxvirus Infection, Part 1
MDedge Dermatology